[go: up one dir, main page]

BRPI0821100A2 - composições e métodos para o tratamento de câncer de bexiga - Google Patents

composições e métodos para o tratamento de câncer de bexiga

Info

Publication number
BRPI0821100A2
BRPI0821100A2 BRPI0821100A BRPI0821100A BRPI0821100A2 BR PI0821100 A2 BRPI0821100 A2 BR PI0821100A2 BR PI0821100 A BRPI0821100 A BR PI0821100A BR PI0821100 A BRPI0821100 A BR PI0821100A BR PI0821100 A2 BRPI0821100 A2 BR PI0821100A2
Authority
BR
Brazil
Prior art keywords
compositions
treatment
methods
bladder cancer
bladder
Prior art date
Application number
BRPI0821100A
Other languages
English (en)
Inventor
Kydonieus Agis
Chaber John
Kuzma Petr
Original Assignee
Endo Pharmaceuticals Solutions
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40433882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0821100(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Endo Pharmaceuticals Solutions filed Critical Endo Pharmaceuticals Solutions
Publication of BRPI0821100A2 publication Critical patent/BRPI0821100A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0821100A 2007-11-30 2008-11-26 composições e métodos para o tratamento de câncer de bexiga BRPI0821100A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99159607P 2007-11-30 2007-11-30
PCT/US2008/084870 WO2009073517A2 (en) 2007-11-30 2008-11-26 Intravesical compositions with valrubicin for the treatment of bladder cancer

Publications (1)

Publication Number Publication Date
BRPI0821100A2 true BRPI0821100A2 (pt) 2017-05-23

Family

ID=40433882

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821100A BRPI0821100A2 (pt) 2007-11-30 2008-11-26 composições e métodos para o tratamento de câncer de bexiga

Country Status (14)

Country Link
US (2) US20090214634A1 (pt)
EP (1) EP2224904A2 (pt)
JP (1) JP6039157B2 (pt)
KR (1) KR20100092016A (pt)
CN (2) CN105147594A (pt)
AR (1) AR069831A1 (pt)
AU (1) AU2008331500B2 (pt)
BR (1) BRPI0821100A2 (pt)
CA (1) CA2706923A1 (pt)
CL (1) CL2008003558A1 (pt)
MX (1) MX2010005862A (pt)
RU (1) RU2542449C2 (pt)
TW (1) TWI510243B (pt)
WO (1) WO2009073517A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009111555A1 (en) * 2008-03-05 2009-09-11 Endo Pharmaceuticals Solutions Inc., Combination treatment for bladder cancer comprisining valrubicin and trospium chloride
PL3010488T3 (pl) * 2013-06-18 2021-11-15 THERMOSOME GmbH Stereospecyficzne lipidy do terapii lokoregionalnej z użyciem długotrwale krążących układów nanonośników wrażliwych na działanie bodźców
CN105982910A (zh) * 2015-01-29 2016-10-05 上海建华精细生物制品有限公司 膀胱保护液制剂及生产工艺
KR102209363B1 (ko) 2016-03-31 2021-01-29 장슈 야홍 메디텍 코퍼레이션 리미티드 암 치료에서 니트록솔린 및 그의 유사체의 화학요법 및 면역요법과의 조합적 사용
CN108498454B (zh) * 2018-04-03 2020-11-06 济川药业集团有限公司 一种蛋白琥珀酸铁口服液及其制备方法
WO2020222139A1 (en) * 2019-04-30 2020-11-05 Trigone Pharma Ltd. Formulations and methods for drug instillation into the bladder and treatment of bladder ailments

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4035566A (en) * 1975-09-25 1977-07-12 Sidney Farber Cancer Institute, Inc. N-trifluoroacetyladriamycin-14-alkanoates and therapeutic compositions containing same
CA1282405C (en) * 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
IE58981B1 (en) * 1985-10-15 1993-12-15 Vestar Inc Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles
US5902604A (en) * 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates
AU749201B2 (en) * 1997-08-28 2002-06-20 Afferon Corporation Urinary incontinence therapy
AU2002323151A1 (en) * 2001-08-13 2003-03-03 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
CA2523475C (en) * 2003-05-28 2013-02-05 Nektar Therapeutics Pharmaceutical formulation comprising a water-insoluble active agent
US20050059613A1 (en) * 2003-07-08 2005-03-17 Bahram Memarzadeh Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
US20050129752A1 (en) * 2003-12-15 2005-06-16 Tty Biopharm Limited Company Use and manufacturing process for liposomal doxorubicin pharmaceutical composition
CA2551813C (en) * 2003-12-24 2014-08-12 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US7901707B2 (en) * 2004-03-15 2011-03-08 Christine Allen Biodegradable biocompatible implant and method of manufacturing same

Also Published As

Publication number Publication date
CL2008003558A1 (es) 2009-12-18
TW200930381A (en) 2009-07-16
RU2542449C2 (ru) 2015-02-20
KR20100092016A (ko) 2010-08-19
TWI510243B (zh) 2015-12-01
CN101951884A (zh) 2011-01-19
US20150190413A1 (en) 2015-07-09
AR069831A1 (es) 2010-02-24
JP2011505370A (ja) 2011-02-24
CN105147594A (zh) 2015-12-16
JP6039157B2 (ja) 2016-12-07
WO2009073517A2 (en) 2009-06-11
WO2009073517A3 (en) 2009-08-13
RU2010126615A (ru) 2012-01-10
EP2224904A2 (en) 2010-09-08
CA2706923A1 (en) 2009-06-11
US20090214634A1 (en) 2009-08-27
AU2008331500B2 (en) 2013-11-21
MX2010005862A (es) 2010-11-30
AU2008331500A1 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
BRPI0921321A2 (pt) métodos para o tratamento de indwcções e tumores
PT2340042E (pt) Métodos e composições para o tratamento de cancro
PT2367561E (pt) Composições e métodos para o tratamento da doença celíaca
BRPI0821660A2 (pt) Combinações de agentes terapêuticos para tratamento de câncer
BRPI0813725A2 (pt) Métodos e composições para tratamento de doenças
LT2478907T (lt) Kompozicijos vėžiui gydyti
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
BRPI1008566A2 (pt) métodos e composições para o diagnóstico e tratamento de câncer
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
BRPI0908026A2 (pt) Métodos para o tratamento de doenças do intestino
BRPI0911112A2 (pt) composições e métodos para o tratamento do câncer de mama
BRPI0908854A2 (pt) composições e métodos para o tratamento de tumor de origem hematopoética
DK2121139T3 (da) Formulations for cancer treatment
BRPI0811589A2 (pt) Composição farmacêutica e método para tratar câncer
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BRPI0810082A2 (pt) 3-imidazolil-indóis para o tratamento de doenças proliferativas
BR112012004979A2 (pt) composições para o tratamento de semente e métodos
BRPI0821779A2 (pt) tratamento terapêutico de câncer
BRPI0822349A2 (pt) composições e métodos para tratar doenças lisossômicas
DK2235002T3 (da) 4-pyridinonforbindelser og anvendelse heraf til behandling af cancer
BRPI0813670A2 (pt) Compostos para tratamento
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
BRPI1010874A8 (pt) composição para o tratamento de câncer de próstata
BRPI0922884A2 (pt) compostos para tratamento de câncer
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/704 (2006.01), A61K 9/00 (2006.01), A61K 9

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 9/00 (2006.01), A61K 9/127 (2006.01), A61K 31

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]